

Conflicts of interest

This study received no specific funding from public, private or non-profit organisations.

REFERENCES

- Bomback AS, Kudose S, D'Agati VD. De novo and relapsing glomerular diseases after COVID-19 vaccination: what do we know so far? *Am J Kidney Dis.* 2021;78(4):477-80, <http://dx.doi.org/10.1053/j.ajkd.2021.06.004>.
- Abramson M, Mon-Wei Yu S, Campbell KN, et al. IgA nephropathy after SARS-CoV-2 vaccination. *Kidney Med.* 2021;3(5):860-3, <http://dx.doi.org/10.1016/j.xkme.2021.05.002>.
- Klomjit N, Alexander MP, Fervenza FP, et al. COVID-19 vaccination and glomerulonephritis. *Kidney Int Rep.* 2021, <http://dx.doi.org/10.1016/j.ekir.2021.09.008>. Online ahead of print.
- Perrin P, Bassand X, Benotmane I, et al. Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy. *Kidney Int.* 2021;100(2):466-8, <http://dx.doi.org/10.1016/j.kint.2021.05.022>.
- Rahim SEG, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. *Kidney Int.* 2021;100(1):238, <http://dx.doi.org/10.1016/j.kint.2021.04.024>.
- McNally A, McGregor D, Searle M, et al. Henoch-Schönlein purpura in a renal transplant recipient with prior IgA nephropathy following influenza vaccination. *Clin Kidney J.* 2013;6(3):313-5, <http://dx.doi.org/10.1093/ckj/sft029>.
- Ponticelli C, Traversi L, Feliciani A, Gesana BM, Banfi G, Tarantino A. Kidney transplantation in patients with IgA mesangial glomerulonephritis. *Kidney Int.* 2001;60(5):1948-54, <http://dx.doi.org/10.1046/j.1523-1755.2001.00006.x>.
- Uffing A, Pérez-Saéz MJ, Jouve T, et al. Recurrence of IgA nephropathy after kidney transplantation in adults. *Clin J Am Soc Nephrol.* 2021;16(8):1247-55, <http://dx.doi.org/10.2215/CJN.00910121>.
- Cazorla-López JM, Wu J, Villanego-Fernández F, et al. IgA nephropathy after renal transplant: recurrences and de novo cases. *Transplant Proc.* 2020;52(2):515-8, <http://dx.doi.org/10.1016/j.transproceed.2019.12.008>.
- Von Visger JR, Gunay Y, Andreoni KA, et al. The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression. *Clin Transplant.* 2014;28(8):845-54, <http://dx.doi.org/10.1111/ctr.12389>.

M. Alonso*, F. Villanego, Ó. Segurado, L.A. Vígara, C. Orellana, T. García, A. Mazuecos

Servicio de Nefrología, Hospital Universitario Puerta del Mar, Cádiz, Spain

* Corresponding author.

E-mail addresses: m.alonsom94@gmail.com (M. Alonso), tino.villanego@gmail.com (F. Villanego), oscarstz86@hotmail.com (Ó. Segurado), luisberbig@gmail.com (L.A. Vígara), cristhian1124@hotmail.com (C. Orellana), teresa_garcia_alvarez@yahoo.es (T. García), mauxiliadora.mazuecos.sspa@juntadeandalucia.es (A. Mazuecos).

2013-2514/© 2024 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). <https://doi.org/10.1016/j.nefro.2024.03.012>



Levotiroxin intoxication; role of extracorporeal techniques

Intoxicación por levotiroxina; papel de las técnicas extracorpóreas

Intoxication is a common disorder in hospital Accident and Emergency departments, especially drug poisoning^{1,2} (50% of cases). Clinical consequences and severity will depend on the characteristics of the poisoning agent and its metabolites, volume of distribution, molecular weight and protein affinity.³ Furthermore, comorbidities such as kidney or liver failure can cause a greater toxicity.

The first step in treating intoxications consists of maintaining the clinical and haemodynamic stability of the patient and avoid intestinal absorption of the toxic compound through

emesis.³ Additional measures are sometimes required, such as extracorporeal blood purification techniques (EBPT), including haemodialysis and haemoperfusion, which promote blood purification of toxins generated endogenously by organ failure or exogenous poisoning.^{4,5}

We present two overlapping cases of levothyroxine poisoning treated with haemoperfusion (HP).

Two female patients aged 50 and 53 years were admitted for attempts at self harm, in the first case (case 1), having taken 100 levothyroxine 50 mcg tablets and in the second case (case 2), 75 levothyroxine 50 mcg tablets. The patients had no relevant previous medical history.

DOI of original article:

<https://doi.org/10.1016/j.nefro.2021.11.006>.

Table 1 – Changes over time in laboratory parameters, patient 1.

	Day 1 HP	Day 2 HP	Day 3 HP	Day 4 HP	Day 5	Day 6	Day 7 discharge
TSH microU/mL	0.76	0.24	0.09	0.05	0.04	0.04	0.04
T4 ng/dl	>7.7	6.53	4.95	4.6	4	3.65	2.85
Hb g/dl	12.4	10.9	9.6	8.6	8.5	9.6	10
Platelets thousand/mm ³	180	58	26 transfusion	90	64	113	165

Hb: haemoglobin; HP: haemoperfusion.

Table 2 – Changes over time in laboratory parameters, patient 2.

	DAY 1 HP	DAY 2 HP	DAY 3	DAY 4 HP	DAY 5	DAY 6	Day 7	AT DISCHARGE
TSH microU/mL	0.06	0.04	0.08	0.04	0.06	0.32	2.69	3.47
T4 ng/dl	4.47	3.45	6.57	2.07	1.7	1.36		
Hb g/dl	14.9	12.1	8.9	9.2	8.2	8.3		
Platelets thousand/mm ³	272	40 transfusion	128	126	106	244		

Hb: haemoglobin; HP: haemoperfusion.

On physical examination, both had a Glasgow Coma Scale score of 13–15 and were haemodynamically stable, with no significant abnormalities in heart rate or pulse oximetry. ECG showed no changes. Blood tests: case 1 T4 >7.70 ng/dl, TSH 0.76 microU/mL; case 2 T4 4.47 ng/dl, TSH 0.06 microU/mL.

Both patients were admitted to the intensive care unit due to the risk of a thyrotoxic crisis; both had placement of femoral catheter within the first four hours to begin HP with activated charcoal. Four three-hour sessions were performed in case 1 and three sessions in case 2, basing the indication on the stability of the patients and their T4 levels. In case 1, after the last HP session she had a T4 level of 4 ng/dl, and at discharge 2.85 ng/dl; and in case 2 after the last HP session she had a T4 of 1.7 ng/dl, and at discharge 1.36 ng/dl (Tables 1 and 2). Both patients remained clinically and haemodynamically stable without emergency measures and without symptoms suggestive of thyrotoxic crisis.

Levothyroxine poisoning is a rare but potentially life-threatening clinical condition. The severity of the poisoning or its toxicity is not necessarily related to the dose of levothyroxine or the initial T4 serum levels.^{6,7} Serum TSH levels do not show the severity of the condition, as it is not suppressed until 48–72 hours later. However, the concentrations of free T4 and free T3 are increases rise from the beginning. It is therefore recommended to test both in the first few hours, as symptoms become evident when T4 is transformed into T3, which explains why patients can remain asymptomatic for the first few hours.^{6,7} Due to the half-life of levothyroxine (seven days), symptoms may appear up to day +11 after ingestion.

The symptoms of levothyroxine poisoning range from being asymptomatic to a wide range of clinical manifestations, including malignant hyperthermia, arrhythmias, acute myocardial infarction, cardiogenic shock, acute psychosis, convulsive states and coma,^{8,9} which is why admission to intensive care units is recommended.

There is no treatment protocol for levothyroxine intoxication; rapid action involving symptomatic treatment and

gastrointestinal decontamination techniques (gastric lavage and administration of activated charcoal), and drugs that inhibit the metabolism of T4 to T3 are essential. In addition, therapies such as plasmapheresis and HP are capable of decreasing the half-life of T4 more quickly.¹⁰

The use of extrarenal blood purification techniques (EBPT) in the treatment of intoxications has been increasing in recent years.¹¹ These techniques are reserved for the following scenarios: exposure to the toxic with potentially lethal high plasma concentrations; toxicity of the substance that cannot be counteracted by an antidote or treatments that prevent absorption and/or elimination; or a high probability of permanent disability or developing toxicity despite supportive measures.¹¹

The principles that govern the elimination of the poison by EBPT are: diffusion; convection; adsorption; and centrifugation. The elimination of the poison depends on its characteristics: volume of distribution; percentage of protein binding; molecular weight; and the velocity of passage from the tissue to the vessel.⁴

Adsorption is a process by which particles located in the blood compartment bind reversibly or irreversibly to the surface of a sorbent column; in the case of HP, this is activated carbon (high adsorption capacity and contact surface area of 300–1,000 m²/g). HP enables the purification of high molecular weight toxins of up to 5,000 Daltons. Its extractive capacity is identical for water-soluble and fat-soluble poisons^{4,11} and is not limited by the degree of binding of the poison to plasma proteins.

HP requires greater systemic anticoagulation than other EBPT and non-selectively adsorbs platelets, white blood cells, calcium and glucose. It has to be replaced every two hours due to cartridge saturation.

Possible complications are common to other EBPT (hypothermia, haemorrhage, arterial hypotension and infection of vascular access routes), with the addition of thrombocytopenia, hypocalcaemia and hypoglycaemia.⁴

In summary, levothyroxine poisoning is potentially life-threatening and requires intensive care. The use of HP could ensure the relatively safe and effective management of potential adverse events deriving from the poisoning.

REFERENCES

- Pastó Cardona L, Martorell Puigserver C, Mercadal Orfila G, Machí Ribes JJ, Jódar Massanès R. Intoxicaciones agudas en el servicio de urgencias de un hospital universitario de nivel III: cambios producidos en los últimos 10 años. *Rev Toxicol*. 2007;24:36–41.
- Burillo-Putze G, Munne P, Dueñas A. National multicentre study of acute intoxication in emergency departments of Spain. *Eur J Emerg Med*. 2003;10:101.
- Burillo G, Munne P, Dueñas A. Intoxicaciones agudas: perfil epidemiológico y clínico, y análisis de las técnicas de descontaminación digestiva utilizadas en los servicios de urgencias españoles en el año 2006 –Estudio HISPATOX–. *Emergencias*. 2008;20:15–26.
- Patel N, Bayliss GP. Developments in extracorporeal therapy for the poisoned patient. *Adv Drug Deliv Rev*. 2015;90:3.
- Ghannoum M, Roberts DM, Hoffman RS. A stepwise approach for the management of poisoning with extracorporeal treatments. *Semin Dial*. 2014;27:362.
- Tunget CL, Clark RF, Turchen SG, Manoguerra AS. Raising the decontamination level for thyroid hormone ingestions. *Am J Emerg Med*. 1995;13(1):9–13.
- Nygaard B, Saedder EA, Dalhoff K. Levothyroxine poisoning - symptoms and clinical outcome. *Basic Clin Pharmacol Toxicol*. 2015;117(4):280–5.
- Beier C, Liebezeit B, Völkl TMK. Intoxikation mit l-thyroxin in suizidaler absicht bei einer jugendlichen. *Klin Padiatr*. 2006;218(1):34–7.
- De Luis DA, Abad L, Aller R. Intoxicación con levotiroxina: Manifestaciones clínicas y manejo terapéutico. *An Med Interna*. 2004;21(1):39–41.
- Savran Y, Mengi T, Keskinilic M. A severe case of levothyroxine intoxication successfully treated in intensive care unit. *J Acute Dis*. 2018;7(4):175.
- Ghannoum M, Hoffman RS, Gosselin. Use of extracorporeal treatments in the management of poisonings. *Kidney Int*. 2018;94(4):P682–688.

Laura Salanova Villanueva *, Pablo Ruano Suárez, Sara Jiménez Blanco

Nefrología, Hospital La Princesa, Madrid, Spain

*Corresponding author.

E-mail addresses: aelita.sv@gmail.com, laura.salanova@salud.madrid.org (L. Salanova Villanueva).

2013-2514/© 2024 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). <https://doi.org/10.1016/j.nefro.2024.03.014>

Familial hypomagnesemia with hipercalciuria and nephrocalcinosis associated with sensorineural hearing loss

Hipomagnesemia familiar con hipercalciuria y nefrocalcinosis asociada a hipoacusia neurosensorial



Dear Editor,

Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC) is a renal tubular disorder characterised by excessive urinary excretion of magnesium and calcium and progressive deterioration in kidney function, with progression to chronic kidney disease attributed to calcium deposits in the renal parenchyma.¹ It is transmitted with autosomal recessive inheritance, associated with the mutation in the CLDN16 and 19 genes, which encode claudin-16 and 19, involved in the paracellular transport of calcium and magnesium through tight junctions, intercellular junction zones of the apical membrane in the thick segment of the ascending limb of the loop of Henle.^{2–5}

The signs and symptoms include those directly related to renal tubular disorders, such as polyuria, polydipsia, lithiasis, nephrocalcinosis and recurrent infections. Other associated symptoms have been reported, such as neuromuscular and eye disorders.^{3–6}

The signs and symptoms include those directly related to renal tubular disorders, such as polyuria, polydipsia, lithiasis, nephrocalcinosis and recurrent infections. Other associated symptoms have been reported, such as neuromuscular and eye disorders.^{3–6}

DOI of original article:
<https://doi.org/10.1016/j.nefro.2021.11.005>.